Here Are a Few Relevant Results "TATA"

More    →
  • The Russian Direct Investment Fund (RDIF), Russias sovereign wealth fund, and Dr. Reddys Laboratories a global pharmaceutical company headquartered out of India, have agreed to cooperate on clinical trials and distribution of Sputnik V vaccine in India. Upon regulatory approval in India, RDIF shall supply to Dr. Reddys 100 million doses of the vaccine. The Sputnik V vaccine, which is based on well studied human adenoviral vector platform with proven safety, is undergoing clinicaltrials for the coronavirus pandemic. Deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India.

    The agreement between RDIF and Dr Reddys reflects the growing awareness of countries and organizations to have a diversified anti-COVID vaccine portfolio to protect their populations.

    G V Prasad, Co-Chairman & Managing Director of Dr. Reddys Laboratoriessaid, “We are pleased to partner with RDIF to bring the vaccine to India. The PhaseI and II clinical trials have shown promising results. We will be conducting Phase-IIItrials in India to ensure safety and efficacy for the Indian population and to meet therequirements of the Indian regulators. Sputnik V vaccine could provide a credibleoption in our fight against COVID 19 in India.”

    Powered by Capital Market - Live News